Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Zachary Frosch, Anthony Masaquel, David Fox, Carolina Reyes, Lourenia Cassoli, Dominic Lai, Kelley Myers, Cooper Bussberg, Krish Patel
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108715390
Cites:
Cited by:
Related to: